The role of glutathione-related genes in lung cancer survival

Abstract Background Lung cancer is the second most common cancer worldwide and the leading cause of death for cancer (18.4%). During the last 30 years, lung cancer incidence and mortality increased in women and decreased in men, because of tobacco smoking exposure. Population survival trend reflects both the influence of disease severity at diagnosis and treatment effectiveness. Some studies reported an increase in global lung cancer survival and linked it to new treatment options. However, change in the overall survival may also reflect a shift towards morphologies with more favorable prognosis. We analyzed overall and morphology specific survival trends for lung cancer to gain insight on the role of new treatments and changing exposures. Methods We analyzed lung cancer 1 y-survival and 3 y-survival after diagnosis in Umbria (890'000 inhabitants) in the period 1994-2016. Population-based data were obtained from the Umbrian Cancer Registry (RTUP), Italy. We estimated relative net survival (Pohar-Perme approach) stratified both for sex and histotype (NSCLC, SCLC, NOS), considering six diagnostic periods from 1994 to 2016 (4 years for period, except 3 in the last one) for 5'268 lung cancer cases (26% women). Results Overall survival by gender resulted 40,5% (1y) and 16.5% (3y) in men, 47,3% (1y) and 23,2% (3y) in women. NSCLC survival increased in women during the period 1994-2016 from 41% to 53% (1y) and from 23% to 33% (3y), and remained unchanged in men. SCLC 3 year-survival did not change significantly neither in women nor in men. Conclusions We did not observe a significant increase in lung cancer survival over a 25 years period. We observed a significant increase in survival probabilities for NSCLC among women only. Thus, our data don't confirm a major role of new treatments in improving lung cancer control. We will provide further analyses for adenocarcinoma and a comparison of incidence and mortality trends to understand the influence of exposures and treatments on survival. Key messages A general increase in lung cancer survival, as could be expected after the introduction of new highly effective treatments is not present in western countries. Reducing exposure to tobacco smoking and environmental pollution remain the main intervention to improve lung cancer control.

Download Full-text

Role of immunotherapy and co-mutations on KRAS-mutant non- small cell lung cancer survival

Journal of Thoracic Disease ◽

10.21037/jtd.2020.04.18 ◽

2020 ◽

Vol 12 (9) ◽

pp. 5086-5095

Author(s):

Idoroenyi Amanam ◽

Isa Mambetsariev ◽

Rohan Gupta ◽

Srisairam Achuthan ◽

Yingyu Wang ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Cancer Survival ◽

Small Cell ◽

Small Cell Lung ◽

Lung Cancer Survival

Download Full-text

The role of receipt and timeliness of treatment in socioeconomic inequalities in lung cancer survival: population-based, data-linkage study

Thorax ◽

10.1136/thoraxjnl-2014-205517 ◽

2014 ◽

Vol 70 (2) ◽

pp. 138-145 ◽

Cited By ~ 26

Author(s):

Lynne F Forrest ◽

Jean Adams ◽

Greg Rubin ◽

Martin White

Keyword(s):

Lung Cancer ◽

Cancer Survival ◽

Data Linkage ◽

Population Based ◽

Linkage Study ◽

Socioeconomic Inequalities ◽

Lung Cancer Survival

Download Full-text

Age disparities in lung cancer survival in New Zealand: the role of patient and clinical factors

10.1101/2020.10.05.20206912 ◽

2020 ◽

Author(s):

Sophie Pilleron ◽

Camille Maringe ◽

Hadrien Charvat ◽

June Atkinson ◽

Eva Morris ◽

...

Keyword(s):

Lung Cancer ◽

New Zealand ◽

Cancer Survival ◽

Age Difference ◽

Stage At Diagnosis ◽

Clinical Factors ◽

Emergency Presentation ◽

Age Disparities ◽

Lung Cancer Survival

AbstractBackgroundAge is an important prognostic factor for lung cancer. However, no studies have investigated the age difference in lung cancer survival per se. We, therefore, described the role of patient-related and clinical factors on the age pattern in lung cancer excess mortality hazard by stage at diagnosis in New Zealand.MethodsWe extracted 22 487 new lung cancer cases aged 50-99 (median age = 71, 47.1% females) diagnosed between 1 January 2006 and 31 July 2017 from the New Zealand population-based cancer registry and followed up to December 2019. We modelled the effect of age at diagnosis, sex, ethnicity, deprivation, comorbidity, and emergency presentation on the excess mortality hazard by stage at diagnosis, and we derived corresponding lung cancer net survival.ResultsThe age difference in net survival was particularly marked for localised and regional lung cancers, with a sharp decline in survival from the age of 70. No identified factors influenced age disparities in patients with localised cancer. However, for other stages, females had a greater age difference in survival between middle-aged and older patients with lung cancer than males. Comorbidity and emergency presentation played a minor role. Ethnicity and deprivation did not influence age disparities in lung cancer survival.ConclusionSex and stage at diagnosis were the most important factors of age disparities in lung cancer survival in New Zealand.Key messagesWhat is the key question?How do patient-related and clinical factors influence age pattern in lung cancer survival?What is the bottom line?Age disparities in lung cancer survival were strongest for females and non-advanced disease. Deprivation, ethnicity, comorbidity, and emergency presentation did not influence age disparities.Why read on?Our findings reinforce the call for a better representation of older adults in clinical trials and a wider use of geriatric assessment to identify patients who will benefit treatment.

Download Full-text